title: Escape from targeted inhibition: the dark side of kinase inhibitor therapy.
authors.affiliation: Ludwig Institute for Cancer Research, University of California San Diego, La Jolla, CA, USA.
authors.forename: Jill
authors.initials: J
authors.lastname: Wykosky
authors.forename: Akitake
authors.initials: A
authors.lastname: Mukasa
authors.forename: Frank
authors.initials: F
authors.lastname: Furnari
authors.forename: Webster K
authors.initials: WK
authors.lastname: Cavenee
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D018797:Cell Cycle Proteins / Q000378:metabolism; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000378:metabolism; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D018797:Cell Cycle Proteins; D047428:Protein Kinase Inhibitors; D066246:ErbB Receptors